Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 3/20 | 0.46 |
| ▸ | DGKA | P23743 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 2/20 | 0.42 |
| ▸ | PAM | P19021 | 2/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
| ▸ | CES2 | O00748 | 4/20 | 0.39 |
| ▸ | CES1 | P23141 | 4/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | NAAA | Q02083 | 2/20 | 0.38 |
| ▸ | DNM1 | Q05193 | 1/20 | 0.38 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | FAAH | O00519 | 1/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | DUSP3 | P51452 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8157293 | 0.89 | LMNA (0.52) | LMNADGKAMAPTPAMMAPK1 | |
| SCHEMBL20918829 | 0.87 | LMNA (0.55) | LMNADGKAMAPTPAMMAPK1 | |
| SCHEMBL31332055 | 0.87 | LMNA (0.55) | LMNADGKAMAPTPAMMAPK1 | |
| SCHEMBL9550379 | 0.87 | LMNA (0.55) | LMNADGKAMAPTPAMMAPK1 | |
| SCHEMBL31620702 | 0.87 | LMNA (0.55) | LMNADGKAMAPTPAMMAPK1 | |
| SCHEMBL20919314 | 0.82 | LMNA (0.50) | LMNADGKAMAPTPAMMAPK1 | |
| SCHEMBL22092398 | 0.82 | LMNA (0.50) | LMNADGKAMAPTPAMMAPK1 | |
| SCHEMBL20918218 | 0.82 | LMNA (0.50) | LMNADGKAMAPTPAMMAPK1 | |
| SCHEMBL9101344 | 0.82 | LMNA (0.50) | LMNADGKAMAPTPAMMAPK1 | |
| SCHEMBL20918469 | 0.82 | LMNA (0.50) | LMNADGKAMAPTPAMMAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040077625-A1 | Novel 1,4-benzothiazepine and 1,5-benzothiazepine compounds as inhibitors of apical sodium codependent bile acid transport abd taurocholate uptake | PHARMACIA CORPORATION | 2004-04-22 | — | — | US | disclosed |
| US-20020183307-A1 | Novel 1,4-benzothiazephine and 1,5-benzothiazepine compounds as inhibitors of apical sodium co-dependent bile acid transport and taurocholate uptake | G.D. SEARLE LLC | 2002-12-05 | — | — | US | disclosed |
| WO-2002008211-A2 | BENZOTHIAZEPINES AND THEIR USE AS ANTIHYPERLIPIDEMICS | G.D. SEARLE, LLC. (US) | 2002-01-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040077625-A1 | Novel 1,4-benzothiazepine and 1,5-benzothiazepine compounds as inhibitors of apical sodium codependent bile acid transport abd taurocholate uptake | SLC10A1, ABCB11, SLC10A2 | LMNA 4425/4885DGKA 2275/4885MAPT 517/4885 |
| US-20020183307-A1 | Novel 1,4-benzothiazephine and 1,5-benzothiazepine compounds as inhibitors of apical sodium co-dependent bile acid transport and taurocholate uptake | SLC10A1, SLC10A2, ABCB11 | LMNA 3151/4885DGKA 2601/4885MAPT 861/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.